Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (691-700 of 993) with videos related to

Pageof 100
Sort By:
World Journal of Urology|November 11, 2025
Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomesQuynh Chi Le, Mattia Longoni, Andrea Marmiroli, et al.
The Lancet. Oncology|August 1, 2014
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Matti Aapro, Lodovico Balducci, et al.
The Prostate|June 2, 2022
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk levelGabriele Sorce, Benedikt Hoeh, Rocco S Flammia, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
Cancers|July 13, 2024
Incidence, Characteristics and Survival Rates of Bladder Cancer after Rectosigmoid Cancer RadiationMario de Angelis, Carolin Siech, Francesco Di Bello, et al.
European Urology Open Science|January 21, 2026
Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate CancerStacey A Kenfield, Nicolas H Hart, Kerry S Courneya, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Annals of Surgical Oncology|October 10, 2023
Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy EraLukas Scheipner, Francesco Barletta, Cristina Cano Garcia, et al.
Pageof 100

Showing results (691-700 of 993) with videos related to

Sort By:
Pageof 100
World Journal of Urology|November 11, 2025
Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomesQuynh Chi Le, Mattia Longoni, Andrea Marmiroli, et al.
The Lancet. Oncology|August 1, 2014
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric OncologyJean-Pierre Droz, Matti Aapro, Lodovico Balducci, et al.
The Prostate|June 2, 2022
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk levelGabriele Sorce, Benedikt Hoeh, Rocco S Flammia, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
Cancers|July 13, 2024
Incidence, Characteristics and Survival Rates of Bladder Cancer after Rectosigmoid Cancer RadiationMario de Angelis, Carolin Siech, Francesco Di Bello, et al.
European Urology Open Science|January 21, 2026
Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate CancerStacey A Kenfield, Nicolas H Hart, Kerry S Courneya, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Annals of Surgical Oncology|October 10, 2023
Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy EraLukas Scheipner, Francesco Barletta, Cristina Cano Garcia, et al.
Pageof 100